Ep 56: Best of 2024: ASCO

Summary

Verbalizing punctuation for laughs...background wood noises ... and out of office replies get things started.

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel record their first in a series of "Best of 2024" and review highlights from the ASCO Annual Meeting. They focus on 4 significant trials: NADINA, COMBI-AD, KEYNOTE 942, and RELATIVITY 048.

James & Sapna discuss the implications of these studies on the melanoma landscape, the importance of long-term follow-up data, and share some light-hearted moments about out-of-office messages.

Keywords

ASCO 2024, melanoma, NADINA trial, neoantigen therapy, checkpoint blockade, out of office messages, long-term follow-up, immunotherapy

Takeaways

Out-of-office messages can be creative and memorable.

The NADINA trial showed a high major pathologic response rate of 60%.

Patient inclusion and trial design in clinical trials can critically affect outcomes (COMBI-AD).

The KEYNOTE 942 trial demonstrated encouraging trends for overall survival.

Triplet checkpoint blockade shows promising PFS results (RELATIVITY 048).

Titles

ASCO 2024 Highlights: Melanoma Trials Reviewed

NADINA, COMBI-AD, KN 942, RELA 048

Chapters

00:00 Introduction and Icebreakers

06:24 ASCO 2024 Highlights: NADINA Trial

13:39 Long-Term Follow-Up: COMBI-AD Study

21:16 Individualized Neoantigen Therapy: KEYNOTE 942

30:23 Triplet Checkpoint Blockade: RELATIVITY 048

31:11 Fact Check Best of 2024: ASCO

31:16 FDA Guidelines on Phase 3 Trials (Listening Series)